
Leslie Samuel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6416447/publications.pdf Version: 2024-02-01



LESLIE SAMUEL

#	Article	IF	CITATIONS
1	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 2022, 19, 146-157.	1.6	7
2	Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database. British Journal of Cancer, 2022, 126, 957-967.	6.4	28
3	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut, 2021, 70, 544-554.	12.1	148
4	Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 2021, 16, 163.	2.7	9
5	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology, 2021, 39, 3693-3704.	1.6	19
6	Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival. Colorectal Disease, 2021, 23, 1326-1333.	1.4	4
7	The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Oncologist, 2020, 25, e451-e459.	3.7	30
8	Young-onset colorectal cancer in the North East of Scotland: survival, clinico-pathological features and genetics. BMC Cancer, 2020, 20, 108.	2.6	7
9	Hypoxia PET/CT and Colorectal Cancer: A Case Report. , 2020, , 1-5.		0
10	Can Haematology Blood Tests at Time of Diagnosis Predict Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer?. Digestive Surgery, 2019, 36, 495-501.	1.2	7
11	A Phase I/ II Feasibility Study of Intravenous Cetuximab in Combination with 5 days Weekly Oral Capecitabine and Preoperative Radiotherapy in Rectal Cancer (XERXES). Archives of Clinical and Biomedical Research, 2019, 04, .	0.2	0
12	Neoadjuvant â€~full dose' oxaliplatin/capecitabine/radiotherapy for MRI selected â€~very' high risk rectal cancers with gross circumferential resection margin (CRM) involvement. European Journal of Surgical Oncology, 2018, 44, S22-S23.	1.0	0
13	Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 2276-2284.	7.0	45
14	Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 162-171.	8.1	47
15	Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	45
16	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 2017, 30, 1287-1298.	5.5	23
17	Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1161-1169.	2.3	5
18	Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. British Journal of Cancer, 2017, 117, 1286-1294.	6.4	22

LESLIE SAMUEL

#	Article	IF	CITATIONS
19	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 2017, 82, 16-24.	2.8	40
20	Neoadjuvant â€~Full Dose' oxaliplatin/capecitabine/radiotherapy for MRI selected â€~very' high risk rectal cancers with gross circumferential resection margin (CRM) involvement. European Journal of Surgical Oncology, 2017, 43, 2221.	1.0	0
21	The expression and prognostic significance of bclâ€2â€associated transcription factor 1 in rectal cancer following neoadjuvant therapy. Histopathology, 2016, 68, 556-566.	2.9	17
22	Patient Evaluation of Nurse-Led Oncology Review Clinics. Journal of Cancer Prevention & Current Research, 2016, 4, .	0.1	0
23	Prognostic value of lymph node ratio and extramural vascular invasion on survival for patients undergoing curative colon cancer resection. British Journal of Cancer, 2015, 113, 212-219.	6.4	58
24	Effect of longer health service provider delays on stage at diagnosis and mortality in symptomatic breast cancer. Breast, 2015, 24, 248-255.	2.2	9
25	Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). Cancer Research, 2015, 75, CT110-CT110.	0.9	10
26	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2015, 33, 669-669.	1.6	11
27	Increased Lymph Node Yield in Colorectal Cancer Is Not Necessarily Associated with a Greater Number of Lymph Node Positive Cancers. PLoS ONE, 2014, 9, e104991.	2.5	11
28	Time from first presentation in primary care to treatment of symptomatic colorectal cancer: effect on disease stage and survival. British Journal of Cancer, 2014, 111, 461-469.	6.4	58
29	Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Annals of Oncology, 2014, 25, 1616-1622.	1.2	44
30	Predictors of anxiety and depression in people with colorectal cancer. Supportive Care in Cancer, 2014, 22, 307-314.	2.2	56
31	Pretreatment and postresection epidermal growth factor receptor (EGFR) pathway mutations in a prospective phase II trial (EXCITE) of preoperative cetuximab-containing chemoradiation (CRT) in locally advanced rectal cancer (LARC) Journal of Clinical Oncology, 2014, 32, 458-458.	1.6	1
32	Developing a community-based intervention to improve quality of life in people with colorectal cancer: a complex intervention development study. BMJ Open, 2013, 3, e002596.	1.9	9
33	Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clinical Cancer Research, 2013, 19, 2541-2550.	7.0	72
34	Patient evaluation of community nurse-led follow-up clinics for colon cancer Journal of Clinical Oncology, 2013, 31, 587-587.	1.6	0
35	Modifiable and fixed factors predicting quality of life in people with colorectal cancer. British Journal of Cancer, 2011, 104, 1697-1703.	6.4	77
36	Preoperative Chemoradiotherapy Using Concurrent Capecitabine and Irinotecan in Magnetic Resonance Imaging–Defined Locally Advanced Rectal Cancer: Impact on Long-Term Clinical Outcomes. Journal of Clinical Oncology, 2011, 29, 1042-1049.	1.6	48

LESLIE SAMUEL

#	Article	IF	CITATIONS
37	Toward shared care for people with cancer: developing the model with patients and GPs. Family Practice, 2011, 28, 554-564.	1.9	65
38	APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer, 2009, 9, 434.	2.6	27
39	A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemotherapy and Pharmacology, 2009, 63, 945-952.	2.3	9
40	Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2). British Journal of Cancer, 2009, 101, 924-934.	6.4	25
41	The spectrum of 5-fluorouracil cardiotoxicity. Anti-Cancer Drugs, 2009, 20, 79-80.	1.4	42
42	EXTRA—A Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 119-126.	0.8	120
43	Randomized Controlled Clinical Effectiveness Trial of Cognitive Behavior Therapy Compared With Treatment As Usual for Persistent Insomnia in Patients With Cancer. Journal of Clinical Oncology, 2008, 26, 4651-4658.	1.6	327
44	A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Annals of Oncology, 2006, 17, 239-245.	1.2	137
45	A phase I study of the trinuclear platinum compound, BBRĩ¿½3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2004, 53, 95-101.	2.3	23
46	Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiotherapy and Oncology, 2004, 73, 153-162.	0.6	154
47	Daunorubicin cardiotoxicity in childhood cancer. Lancet, The, 1998, 352, 1150.	13.7	15
48	Solitary Extramedullary Plasmacytoma. New England Journal of Medicine, 1997, 337, 1174-1174.	27.0	4
49	Role of transesophageal echocardiography in diagnosis and management of central pulmonary artery thromboembolism. American Journal of Cardiology, 1993, 71, 1115-1118.	1.6	25